Evofem announces license and supply agreement with Windtree Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2025
0mins
License Agreement: Evofem Biosciences has signed a License and Supply Agreement with Windtree Therapeutics, which will help reduce the manufacturing costs of its FDA-approved contraceptive gel, PHEXXI, by 55% to 60%.
Commercialization Efforts: Evofem retains ownership of PHEXXI and continues to market it in the U.S. while also expanding internationally, including a partnership with Pharma 1 Drug Store to launch the product in the UAE.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
